IQVIA leads $40m financing round for RWE and data analytics company Cota

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/jansucko)
(Image: iStock/jansucko)
The healthcare real-world evidence (RWE) and data analytics company Cota has completed a Series C financing round led by IQVIA.

EW Healthcare Partners, a growth equity firm, was also a “major” participant in the financing round, which raised $40m.

The funds will be used to advance Cota’s proprietary Cota Nodal Address (CNA) system, a precision disease classification system built on the company’s real-world data set, according to Cota.

The money will help scale its solutions across healthcare providers, payers and life sciences companies, according to the company.

Cota’s CNA-based Real World Evidence (RWE) offerings include Cota Research, Cota Payer Solution, Cota Provider Solution and Cota Life Sciences.

"We are excited to support Cota's unique oncology analytic environment and real-world data capabilities​," said Jon Resnick, president, real-world and analytics solutions, IQVIA, in a press release.

"We have been investing in applying data science to accelerate drug development, ensure patient access to innovative therapies, and make value and outcomes more transparent to align all healthcare stakeholders​,” said Resnick, adding that the investing in Cota is consistent with this vision.

As part of its participation, IQVIA has also gained a seat on Cota’s board of directors.

IQVIA is not providing any additional comment on the investment at this time.

Memorial Sloan Kettering Cancer Center also participated in the round, joining existing investors including Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health, and Atoc Holdings.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more